On this page
Typically prepared by a compounding pharmacy under the direction of a licensed healthcare professional — not an FDA-approved finished product in this form.
Overview
Product & regulatory status
Geref had FDA approval; a compounded sermorelin product is not that approved finished product.
Pituitary stimulation
Sermorelin is GHRH1-29; the human challenge study demonstrates stimulation of GH release rather than replacement with GH itself. [1]
What the evidence shows
Historical clinical context
FDA’s Geref record concerns pediatric growth-hormone deficiency with growth failure. This history does not establish an anti-aging indication. [2]
What physiology studies measured
A study in eight healthy men compared acute GH responses after GHRH1-29 and GHRP-2 challenges. It measured hormone release over hours, not improvements in muscle, sleep, or lifespan. [1]
What remains unknown
A response on a hormone test does not establish a meaningful clinical benefit, and adult wellness use needs evidence specific to that objective.
Safety
Compounded product quality
FDA does not preapprove compounded drugs for safety, effectiveness, or quality. Historical Geref findings cannot establish the quality or handling requirements of a different preparation. [4]
Historical versus current supply
The FDA listing identifies injectable Geref products. Their historical shelf-life information should not be reused for a different compounded vial. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [5]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [6]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Was Geref withdrawal proof that sermorelin was unsafe?
FDA’s discontinued-product listing records a determination that Geref was not withdrawn for safety or effectiveness reasons. That still does not approve new compounded products.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers1995 · Primary research · PubMed
- Geref (sermorelin acetate): orphan designation and approval recordFDA · Historical approval record
- Approved Drug Products with Therapeutic Equivalence EvaluationsFDA · March 2020 · Geref discontinued-product entries
- Human Drug CompoundingFDA · Finished-product distinction
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.